$3.1 Billion is the total value of BRAIDWELL LP's 70 reported holdings in Q1 2024. The portfolio turnover from Q4 2023 to Q1 2024 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GUARDANT HEALTH INCnote11/1 | $183,591,669 | -2.9% | 268,252,000 | 0.0% | 5.92% | -14.8% | ||
| NOVOCURE LTDnote11/0 | $124,627,695 | +5.7% | 135,834,000 | 0.0% | 4.02% | -7.3% | ||
| SAREPTA THERAPEUTICS INCnote 1.250% 9/1 | $59,309,620 | +15.1% | 50,666,000 | 0.0% | 1.91% | +1.1% | ||
| BRIDGEBIO PHARMA INCnote 2.250% 2/0 | $55,137,279 | -3.8% | 67,294,000 | 0.0% | 1.78% | -15.6% | ||
| TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $49,645,727 | +4.1% | 56,031,000 | 0.0% | 1.60% | -8.7% | ||
| KARYOPHARM THERAPEUTICS INCnote 3.000%10/1 | $35,793,199 | +8.5% | 65,976,000 | 0.0% | 1.15% | -4.8% | ||
| KIDS | ORTHOPEDIATRICS CORP | $32,302,573 | -10.3% | 1,107,770 | 0.0% | 1.04% | -21.3% | |
| NVRO | NEVRO CORP | $25,650,754 | -32.9% | 1,776,368 | 0.0% | 0.83% | -41.1% | |
| CGEM | CULLINAN ONCOLOGY INC | $21,144,340 | +67.2% | 1,240,865 | 0.0% | 0.68% | +46.8% | |
| TOURMALINE BIO INC | $20,766,178 | -12.5% | 906,820 | 0.0% | 0.67% | -23.3% | ||
| SPYRE THERAPEUTICS INC | $19,533,950 | +76.3% | 515,000 | 0.0% | 0.63% | +54.8% | ||
| CUTERA INCnote 4.000% 6/0 | $6,435,138 | -1.7% | 29,000,000 | 0.0% | 0.21% | -13.8% | ||
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $5,927,170 | -20.7% | 7,843,285 | 0.0% | 0.19% | -30.3% | |
| OM | OUTSET MED INC | $5,328,948 | -59.0% | 2,400,427 | 0.0% | 0.17% | -63.9% | |
| ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $4,357,543 | -34.5% | 1,357,490 | 0.0% | 0.14% | -42.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2024-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GUARDANT HEALTH INC | 7 | Q2 2024 | 6.9% |
| NOVOCURE LTD | 7 | Q2 2024 | 4.3% |
| BRIDGEBIO PHARMA INC | 7 | Q2 2024 | 5.1% |
| XENON PHARMACEUTICALS INC | 7 | Q2 2024 | 3.1% |
| VAXCYTE INC | 7 | Q2 2024 | 3.0% |
| NUVASIVE INC | 7 | Q2 2024 | 3.5% |
| ALPHATEC HLDGS INC | 7 | Q2 2024 | 3.6% |
| GLAUKOS CORP | 7 | Q2 2024 | 3.0% |
| ALIGN TECHNOLOGY INC | 7 | Q2 2024 | 2.6% |
| IRHYTHM TECHNOLOGIES INC | 7 | Q2 2024 | 2.2% |
View BRAIDWELL LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
View BRAIDWELL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.